21369-76-6

Basic information

• Product Name: α-Chloroacrylic acid chloride
• Synonyms: α-Chloroacrylic acid chloride;2-Propenoyl chloride, 2-chloro-
• CAS NO: 21369-76-6
• Molecular Formula: C₃H₂Cl₂O
• Molecular Weight: 124.95338
• Mol File: 21369-76-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 107.7°Cat760mmHg
• Flash Point: 40.6°C
• Appearance: /
• Density: 1.345g/cm³
• Vapor Pressure: 26.8mmHg at 25°C
• Refractive Index: 1.456
• CAS DataBase Reference: α-Chloroacrylic acid chloride(CAS DataBase Reference)
• NIST Chemistry Reference: α-Chloroacrylic acid chloride(21369-76-6)
• EPA Substance Registry System: α-Chloroacrylic acid chloride(21369-76-6)

Safety Data

• Hazardous Substances Data: 21369-76-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C3H2Cl2O/c1-2(4)3(5)6/h1H2

Upstream product

• 598-79-8 2-Chloroacrylic acid 
• 98-88-4 benzoyl chloride 
• 7623-13-4 2,3-dichloropropionyl chloride 
• 91-66-7 N,N-diethylaniline 
• 3266-39-5 2,3,3-trichloro-2-propen-1-ol 
• 32997-86-7 2-chloroacrylic acid sodium salt 
• 79-37-8 oxalyl dichloride 
• 75-44-5 phosgene 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 687-46-7 ethyl 2-chloroacrylate 
• 100955-24-6 2-chloro-acrylic acid-(4-cyclohexyl-phenyl ester) 
• 79751-44-3 2-chloro-N-phenylacrylamide 
• 6090-85-3 2-chloro-N-(4-chlorophenyl)-2-propenamide 
• 93809-45-1 4--N-methyl-amino>-4'-nitroazobenzol 
• 125213-26-5 (+/-)-2-(benzyloxycarbonyl)-6-ethyl-7-exo-chloro-2-azabicyclo<2.2.2>oct-5-ene-7-endo-carboxylic acid methyl ester 
• 125213-26-5 (+/-)-2-(benzyloxycarbonyl)-6-ethyl-7-endo-chloro-2-azabicyclo<2.2.2>oct-5-ene-7-exo-carboxylic acid methyl ester 
• 128826-70-0 (+/-)-3-(Benzyloxycarbonyl)-7-chloro-3-azabicyclo<4.2.0>oct-4-ene-7-carboxylic Acid Methyl Ester 
• 89129-21-5 (+/-)-2-(Benzyloxycarbonyl)-7-exo-chloro-2-azabicyclo<2.2.2>oct-5-ene-7-endo-carboxylic Acid Methyl Ester 
• 89129-21-5 (+/-)-2-(Benzyloxycarbonyl)-7-endo-chloro-2-azabicyclo<2.2.2>oct-5-ene-7-exo-carboxylic Acid Methyl Ester 
• 89129-21-5 N-benzyloxycarbonyl-7-chloro-7-methoxycarbonyl-2-azabicyclo[2.2.2]oct-5-ene 
• 98153-90-3 1-isopropyl-1H-inden-1-ol 
• 98153-92-5 2a-hydroxy-7b-isopropyl-1,2a,7a,7b-tetrahydro-2H-cyclopentinden-2-one 
• 57441-23-3 1-Chloro-2,2-dimethyl-4-phenyl-cyclohex-3-enecarbonyl chloride 

Relevant articles and documents

ELECTROPHILIC REARRANGEMENT OF TRICHLOROALLYL ALCOHOL

-

Direct Regio- and Diastereoselective Synthesis of δ-Lactams from Acrylamides and Unactivated Alkenes Initiated by RhIII-Catalyzed C?H Activation

We report a RhIII-catalyzed regio- and diastereoselective synthesis of δ-lactams from readily available acrylamide derivatives and unactivated alkenes. The reaction provides a rapid route to a diverse set of δ-lactams in good yield and stereoselectivity, which serve as useful building blocks for substituted piperidines. The regioselectivity of the reaction with unactivated terminal alkene is significantly improved by using Cpt ligand on the RhIII catalyst. The synthetic utility of the reaction is demonstrated by the preparation of a potential drug candidate containing a trisubstituted piperidine moiety. Mechanistic studies show that the reversibility of the C?H activation depends on the choice of Cp ligand on the RhIII catalyst. The irreversible C?H activation is observed and becomes turnover-limiting with [CptRhCl2]2 as catalyst.

Quinoline and quinazoline derivatives, preparation method, intermediate, composition and use thereof (by machine translation)

The invention discloses a quinoline and quinazoline derivative I, a preparation method, an intermediate C, composition and an application. The preparation method comprises two methods, wherein the first method comprises steps as follows: 1, a compound A and a compound B react in a solvent under the action of alkali 1 to obtain a compound C; and 2, the product C obtained in the step 1 reacts with a compound D under the action of alkali 2; and the second comprises step as follows: the compound A and a compound E react in the solvent under the action of the alkali 1. The invention further provides the application of the compound represented in formula I or medicine composition in preparation of an EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor, an A431 or H1975 cell proliferation inhibitor or medicine for preventing or treating tumor diseases. The provided compound has better antitumor activity.